NeuroAiD es seguro y se tolera bien.
Referencias
1. . Young S y cols. Safety profile of MLC601 (NeuroAiD) in acute ischemic stroke patients: A Singaporean substudy of the Chinese medicine NeuroAiD efficacy on stroke recovery study. Cerebrovascular Diseases. 2010;30:1-6. 2. Gan R y cols. Danqi Piantan Jiaonang does not modify haemostasis, haematology, and biochemistry in normal subjects and stroke patients. Cerebrovascular Diseases. 2008;25:450-456. 3. Chen C y cols. Chinese medicine NeuroAiD efficacy on stroke recovery: A double-blind, placebo-controlled, randomized study. Stroke. 2013a;44:2093-2100 4. Venketasubramanian N y cols. CHInese medicine NeuroAiD efficacy on stroke recovery – Extension study (CHIMES-E): A multicenter study of long-term efficacy. Cerebrovascular Diseases. 2015;39:309-318. 5. Shahripour RB y cols. A Randomized Trial to Assess the Long-Term Safety of NeuroAiD among Caucasian Patients with Acute Ischemic Stroke. Chin J Integr Med. 2014;20(11): 812-817.
Exención de responsabilidad: NeuroAiD™ II es una marca comercial de Moleac. MLC601 y MLC901 son 2 formulaciones patentadas diferentes cuya equivalencia farmacológica se ha demostrado y que se denominan NeuroAiD en esta página web.